Form 4: United Therapeutics COO Exercises Options and Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock on December 23, 2024.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
• The transactions involved the exercise of 10,000 stock options at a price of $111 per share.
• A total of 10,000 shares were acquired through option exercises and then sold in multiple transactions at prices ranging from $356.01 to $364.12.
• The sales were executed through a trust where Mr. Benkowitz is a co-trustee and beneficiary, and another trust where his family members are beneficiaries.
• Following these transactions, Mr. Benkowitz's beneficial ownership of common stock through the trusts was reduced.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive under a pre-arranged plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for corporate insiders who often use 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading. It is common for executives to exercise options and sell shares for personal financial planning.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among corporate executives to manage their stock transactions and avoid potential insider trading issues.
• The reported transactions are similar to those of other executives at publicly traded companies who exercise stock options and sell shares as part of their compensation and financial planning.
• The price range of the sales is within the typical range for market transactions of this type.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

stock options, Rule 10b5-1, insider trading, share sale, United Therapeutics, UTHR, Michael Benkowitz